4.1 Article

The Economic Consequences of Acute Kidney Injury

期刊

NEPHRON
卷 137, 期 4, 页码 297-301

出版社

KARGER
DOI: 10.1159/000475607

关键词

Acute kidney injury; Costs; Economics; Hospital care

资金

  1. Kidney Research Scientist Core Education and National Training Program Post-Doctoral Fellowship
  2. Kidney Foundation of Canada
  3. Canadian Society of Nephrology
  4. Canadian Institutes of Health Research
  5. NIDDK [K24 DK085446]
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079337, K24DK085446] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Acute kidney injury (AKI) is an increasingly common condition associated with poor health outcomes. Combined with its rising incidence, AKI has emerged as a major public health concern with high human and financial costs. In England, the estimated inpatient costs related to AKI consume 1% of the National Health Service budget. In the United States, AKI is associated with an increase in hospitalization costs that range from $5.4 to $24.0 billion. The most expensive patients are those with AKI of sufficient severity to require dialysis, where cost increases relative to patients without AKI range from $11,016 to $42,077 per hospitalization. Even with these high costs, significant hospital-level variation still exists in the cost of AKI care. In this article, we review the economic consequences of AKI for both the general and critically ill AKI population. Our primary objective is to shed light on an opportunity for hospitals and policymakers to develop new care processes for patients with AKI that have the potential to yield substantial cost savings. By exposing the high rates of death and disability experienced by affected patients and the immense financial burden attributable to AKI, we also hope to motivate scientists and entrepreneurs to pursue a variety of innovative therapeutic strategies to combat AKI in the near term. (C) 2017 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据